Molecular Partners: Pioneering Targeted Radiopharmaceuticals
Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners, a Roadshow Partner of Venture Leaders Biotech, has spent two decades developing...
Read more
Meet Stefan Imseng, Co-Founder of Aukera. The biotech startup focuses on developing a first-in-class inhibitor to address neurological disorders and cancers. In June, Stefan will join nine other Biotech innovators on a business development and investor roadshow in Boston.
Name: Stefan Imseng
Location: Basel
Nationality: Swiss
Graduated from: University of Basel (PhD)
Job title: CEO & Co-Founder
Number of employees: 4
Money raised: CHF 3M (grants and investments)
Can you tell us who your product or solution helps, and how?
Aukera's solution follows a fundamentally novel strategy to target mTORC1 - a prime target in several human diseases. We leverage AI-driven protein design to enable and accelerate lead discovery for targets that have traditionally been hard to drug.
What market are you addressing and what is the potential of your startup in that market?
Aukera is focused on developing new treatments for rare neurological disorders and cancer. Our lead program has first-in-class potential and aims to deliver disease-modifying therapies for patients with high unmet medical needs.
Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners, a Roadshow Partner of Venture Leaders Biotech, has spent two decades developing...
Read more
Twenty years after co-founding Molecular Partners (MP), Patrick Amstutz and Michael Stumpp reflect on building a company around a novel drug class—DARPin therap...
Read more
Meet Michael Zering, Co-Founder of Apricot Therapeutics. The biotech startup aims to become the "Google Maps" of the tumor cell by combining drug perturbations,...
Read more
Meet Sasha Melkonyan, Co-Founder of Nerai. The biotech startup develops new, highly personalized gene-editing tools designed to provide lasting treatments for d...
Read more